Labcorp and Pillar Biosciences have signed an agreement to offer genomic cancer testing based on Pillar's next-generation sequencing (NGS) technology.
Under the deal, Pillar will provide its OncoReveal Essential myeloproliferative neoplasm (MPN) panel. The test simultaneously measures for DNA mutations across multiple genes, according to the vendor.
